Skip to main content

Sound Advice: May 20, 2020

Vaccine In Sight?

Why do stock prices change?  Over extended periods, the main reasons are changes in underlying profits.  That's what Wall Streeters call fundamentals. When companies make more money, their shares rise . . . over time.  And vice-versa.

But on a day-to-day basis, fundamentals are often meaningless.  So on days when the Dow Jones Average rises or falls 5% or more, you can be sure that there's no corresponding change in fundamentals.

What's going on when this happens?  It's all about fear and greed, the polar opposite forces that rule the short term.  And now, once again, a tidbit of apparently good news has investors working on a big one-day lift-off.

The news is from Moderna, a Cambridge, Massachusetts company that has had encouraging results from a Phase One trial of a new vaccine for Covid-19.  This vaccine uses messenger RNA, or mRNA, to stimulate production of neutralizing antibodies.

The initial test included only 45 participants, but the vaccine produced antibodies in all of them.  Three different dosages were evaluated.  All three appear to have led to the desired result, but the highest dosage had some temporary side effects.

Moderna is now moving toward a Phase Two trial with 600 participants.  If the Phase Two trial is successful, the Phase Three trial, which would have thousands of participants, could begin in July.  In addition to concern about efficacy, there will be a focus on side effects as well as additional data needed on the possibility of reinfection after recovering from the virus.

Phase One trials, the initial human trials, deal with safety and efficacy.  Phase Two trials deal with efficacy and side effects.  Phase Three deals with efficacy, effectiveness, and safety.

One more thing about Moderna: Following the vaccine news, investors bid up the stock by 20%. Moderna announced the filing of a $1.25 billion offering of common shares to provide funding for manufacturing and distribution.  That news led to a pullback in the stock's price.

It's important to put all of this in perspective.  Even with the most extraordinary efforts, the earliest dates for initial availability of this vaccine would be the first quarter of 2021.  And it will take exceptional coordination of manufacturing and distribution to reach the point of general availability.  That might well be a year or more away.

In the interim, we will have to continue dealing with precautions such as social distancing and masks to guard against the exposure to infection.  This is not a pleasant prospect, but it is an essential prerequisite.

Life in 2020 has been and will continue to be different.  Business conditions are dreadful and digital life has temporarily replaced real life.

As time passes and confidence in the coming recovery builds, there will be a more substantial basis for Wall Street enthusiasm.  In the quarters ahead, we will have to bridge the broad abyss of trying business times.

Better times lie ahead, beyond the abyss.

N. Russell Wayne, CFP

www.soundasset.com








Comments

Popular posts from this blog

Sound Advice: January 3, 2025

2025 Market Forecasts: Stupidity Taken To An Extreme   If you know anything about stock market performance, you can only gag at the nonsense “esteemed forecasters” are now putting forth about the prospective path of stocks in the year ahead.   Our cousins in the UK would call this rubbish.   I would not be as kind. Leading the Ship of Fools is the forecast from the Chief Investment Strategist at Oppenheimer who is looking for a year-end 2025 level for the Standard & Poor’s Index of 7,100, a whopping 21% increase from the most recent standing.   Indeed, most of these folks are looking for double-digit gains.   Only two expect stocks to weaken. In the last 30 years, the market has risen by more than 20% only 15 times.   The exceptional span during that time was 1996-1999, which accounted for four of those jumps.   What followed in 2000 through 2002 was the polar opposite: 2000:      -9.1% 2001:     -11.9% ...

Sound Advice: March 10, 2021

The ABCs of Stock Picking After decades of analyzing stocks (and funds) and investing for clients, I'm happy to share in plain English what's involved, what works, and what doesn't.  Keep in mind the reality that successful stock picking is an effort to maintain a good batting average. In baseball, a batting average of .300 or better is considered quite good.  With stock picking, you need to do better than .600, which means you have many more winners than losers. No one gets it right all of the time.  It's not even close.  Wall Street shops all have their recommended lists and the financial media regularly hawk 10 stocks to buy now. Following that road usually is a direct route to disaster.  Don't be tempted. Let's begin with the big picture: The stock market goes up and down over time, but the long-term trend is up.  When there's a rally under way, everyone feels like a genius.  When the market hits an air pocket, though, with few exception...

Sound Advice: June 17, 2020

Rock and a Hard Place Regardless of your age, impressions from childhood linger.  As the first days of summer approach, we all remember the feeling that accompanied the end of a school year.  Yet as much as many of us would like to believe we again have the summertime freedom to do as we wish, the reality is quite the opposite. Although months of confinement and limitations on social interaction have increased our personal discomfort and severely impacted the business community, our current situation is not analogous to the end of any school year.  It’s quite the opposite. There is every reason to continue wearing face masks, social distancing, and avoiding close contact with others.  Nothing suggests that we can modify our behavior significantly or resume patterns of daily living we enjoyed only a few months ago. There are no meaningful advances in medical treatments.  At best, there are attempts to combine different approaches...